CAJ | 학술논문

目的：观察小剂量尿激酶（UK）联合低分子肝素钙治疗进展性脑梗死的临床疗效及安全性。方法选取发病6 h后症状仍旧没有得到改善的40例急性脑梗死患者作为研究对象，随机分为对照组（接受常规治疗）、观察组（在常规治疗基础上应用小剂量尿激酶联合低分子肝素钙）。比较2组临床疗效以及不良反应发生情况。结果观察组总有效显著高于对照组（P<0.05）；观察组有2例患者发生局部皮下瘀血，没有给治疗带来不利影响，无严重出血性并发症发生。结论在常规治疗基础上应用小剂量尿激酶联合低分子肝素钙治疗进展性脑梗死，不仅疗效显著，而且具有较高的安全系数。
목적：관찰소제량뇨격매（UK）연합저분자간소개치료진전성뇌경사적림상료효급안전성。방법선취발병6 h후증상잉구몰유득도개선적40례급성뇌경사환자작위연구대상，수궤분위대조조（접수상규치료）、관찰조（재상규치료기출상응용소제량뇨격매연합저분자간소개）。비교2조림상료효이급불량반응발생정황。결과관찰조총유효현저고우대조조（P<0.05）；관찰조유2례환자발생국부피하어혈，몰유급치료대래불리영향，무엄중출혈성병발증발생。결론재상규치료기출상응용소제량뇨격매연합저분자간소개치료진전성뇌경사，불부료효현저，이차구유교고적안전계수。
Objective To observe the small dose of urokinase(UK) with low molecular weight heparin calcium in the treatment of clinical efficacy of progressive cerebral infarction and security. Methods 6h after the onset of symptoms is still not improved in 40 cases of acute cerebral infarction patients for the study , with randomization of the conventional approach to equality are divided into two groups, one group is defined as the control group , all patients received conventional treatment;another group is defined as the observation group , all patients received conventional therapy in addition to , but also accept small dose of urokinase combined with low molecular weight heparin therapy. Compare clinical efficacy and adverse events. Results In total efficiency , the observation group (90%) than the control group(70%), P<0.05;observation group 2 patients localized subcutaneous congestion, no adverse effects to the treatment , addition of in addition, the severity of the bleeding complications did not occur. Conclusion For the treatment of progressive cerebral infarction , the combination therapy used in the observation group than conventional therapies advantage , not only a significant effect,but also has a high safety factor.